Amneal achieves second u.s. biosimilars approval with alymsys® (bevacizumab-maly)

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that the u.s. food and drug administration (fda) has approved the company's biologics license application (bla) for bevacizumab-maly, a biosimilar referencing avastin®. the product will be marketed under the proprietary name alymsys® and represents the third bevacizumab biosimilar approved in the u.s. alymsys® was developed by mabxience, a global biotech company with over a
AMRX Ratings Summary
AMRX Quant Ranking